嵌合抗原受体基因修饰的T细胞治疗复发或难治性急性白血病的临床疗效及可行性

发布时间：2018-06-05 22:05

本文选题：嵌合抗原受体 + 急性白血病　；参考：《中国科学:生命科学》2017年10期

【摘要】：经过几十年的医学发展,急性白血病的治疗手段有了很大的改善,但是复发率依然维持在一个高的水平;而面对复发这种局面,治疗的方案主要包括二次异基因造血干细胞移植和供者淋巴细胞输注(DLI)这两种治疗方式,主要是调控移植物抗白血病效应,但是治疗效果有限.DLI总的缓解率仅是15%~42%;两年总生存期是15%~20%,而且伴有DLI相关的毒副作用,如移植物抗宿主病.因此,发展新的靶向治疗策略治疗复发或难治性白血病迫在眉睫.嵌合抗原受体基因修饰的T细胞治疗白血病成为一种很有前景的治疗方法,被基因修饰过的T细胞具备识别肿瘤相关抗原的能力,而且可以突破传统治疗的限制.本文通过对当前嵌合抗原受体基因修饰的T细胞治疗的理解,讨论其相关的有效性及毒副作用.
[Abstract]:After decades of medical development, the treatment of acute leukemia has been greatly improved, but the recurrence rate remains at a high level. The therapeutic schemes mainly include secondary allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusion (DLI), which mainly regulate graft anti-leukemia effect. However, the overall remission rate of DLI was only 15%, and the total survival time of two years was 15% and 20% with DLI related side effects, such as graft-versus-host disease. Therefore, the development of new targeted treatment strategies for recurrent or refractory leukemia is imminent. Chimeric antigen receptor gene modified T cell therapy has become a promising treatment for leukemia. The genetically modified T cells have the ability to recognize tumor-associated antigens and can break through the limitations of traditional therapy. In this paper, the efficacy and side effects of chimeric antigen receptor gene modified T cell therapy were discussed.
【作者单位】：军事医学科学院附属医院造血干细胞移植科;
【基金】：国家“十二五”“重大新药创制”科技重大专项课题(批准号:2011ZX09102-001-29) 北京市临床应用研究项目(批准号:Z131107002213148)资助
【分类号】：R733.71

【相似文献】